Frankfurt
23.06.26 | 08:05
0,078 Euro
-3,71 % -0,003
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | NextCell Pharma AB: Interim Report first quarter 2026 | 269 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Interim report for the first quarter 2026. The report is available on the company's website: www.nextcellpharma.com. NextCells share... ► Artikel lesen | |
| 27.05. | Nextcell Pharma AB: Nextcell Pharma AB (publ) Annual General Meeting 2026 | 239 | GlobeNewswire (Europe) | On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 ("NextCell" or the "Company"), was held. A summary of the resolutions adopted at the Annual General... ► Artikel lesen | |
| 06.05. | FUJIFILM Biosciences and NextCell Launch Global Research-Use Stromal Cell Platform | 3 | Contract Pharma | ||
| 06.05. | NEXTCELL PHARMA AB: NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 4 | Cision News | ||
| 06.05. | FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 440 | Business Wire | Collaboration results in platform to help researchers overcome challenges in MSC research NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product... ► Artikel lesen | |
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 04.05. | NEXTCELL PHARMA AB: NextCell Pharma publishes Annual Report 2024/2024 | 1 | Cision News | ||
| 13.03. | NEXTCELL PHARMA AB: ProTrans Phase II COVID-19 Trial Accepted for Publication in Cytotherapy | 3 | Cision News | ||
| 03.03. | NEXTCELL PHARMA AB: NextCell Pharma presents historical quarterly figures | 2 | Cision News | ||
| 26.02. | NextCell Pharma AB: NextCell publishes Year-End Report 2024/2025 | 236 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Year-End Report for the extended financial year September 1, 2024 - December 31, 2025. The report is available on the company's... ► Artikel lesen | |
| 17.02. | NEXTCELL PHARMA AB: NextCell Participating in JETRO's Japan Entry Acceleration Program | 1 | Cision News | ||
| 03.02. | NextCell Pharma AB: Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes | 169 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with... ► Artikel lesen | |
| 21.01. | NextCell Pharma AB: NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market | 179 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans in adult patients... ► Artikel lesen | |
| 21.01. | NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL) | 1 | Cision News | ||
| 15.01. | NextCell Pharma AB: Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes | 213 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation... ► Artikel lesen | |
| 02.12.25 | NextCell Pharma AB: NextCell initiates collaboration with OptiCell - strengthening its cell-handling operations | 205 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") has entered into a collaboration agreement with OptiCell Solutions AB ("OptiCell") regarding the handling, freezing, storage, and transport of cell products... ► Artikel lesen | |
| 20.11.25 | NextCell Pharma AB: NextCell Pharma appoints Eric Gustafsson as new CFO | 503 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and... ► Artikel lesen | |
| 30.10.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 4 2024/2025 | 205 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 - August 31, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 18.09.25 | NextCell Pharma AB: NextCell Pharma AB announces CFO transition | 229 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company's CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout... ► Artikel lesen | |
| 24.07.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 3 2024/2025 | 301 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 - May 31, 2025. This English version of the Interim Report is a translation of the Swedish version.... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,64 | +46,76 % | Pharma-Milliardendeal: AbbVie kauft Biotech-Hoffnung - Übernahmeziel schießt um fast 50 % hoch! | © Foto: Nikos Pekiaridis - NurPhotoAbbVie übernimmt Apogee Therapeutics für rund 10,9 Milliarden US-Dollar. Der Deal soll das Immunologiegeschäft stärken und neue Wachstumstreiber schaffen.AbbVie sichert... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 99,02 | +9,50 % | Truist reiterates Kymera stock Buy rating after AbbVie deal | ||
| SUMMIT THERAPEUTICS | 14,255 | +3,67 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TANGO THERAPEUTICS | 28,250 | +1,00 % | Tango Therapeutics appoints Robert Azelby to board of directors | ||
| TREVI THERAPEUTICS | 17,440 | +1,34 % | Trevi Therapeutics Aktie erreicht Rekordhoch von 16,13 USD | ||
| ABSCI | 7,930 | +7,02 % | Leerink Starts Coverage on Absci Corporation (ABSI) | ||
| PRAXIS PRECISION MEDICINES | 299,41 | +6,06 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| IMMUNOVANT | 38,055 | +7,68 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| ERASCA | 14,720 | +7,68 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,950 | +4,08 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 22,920 | +19,31 % | MoonLake Immunotherapeutics AG: MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 | Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab's (SLK) potential best-in-class and best-in-disease profile... ► Artikel lesen | |
| MBX BIOSCIENCES | 44,430 | +3,25 % | MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,010 | +3,05 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| DISC MEDICINE | 72,26 | +2,08 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 47,370 | +5,03 % | Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More |
Das Unternehmen NEXTCELL PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,078 Euro und damit -3,71 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.